Antibody Hotspot Design for Precise Epitope Binding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for computational antibody design lack the ability to achieve precise control over affinity, specificity, and binding mode, making it challenging to develop antibodies that target pre-selected epitopes with high affinity.

Innovation Solution

A novel computational framework that identifies hotspot residues and uses database screening and CDR loop swapping to design antibodies with precise control over binding mode, optimizing affinity through iterative modifications and superimposition of candidate antibody structures.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If computational antibody design methods are used, then the ability to control binding mode is improved, but the precision of affinity control remains insufficient

Engineering Contradiction:
Improvecontrol over binding modeVSAvoidprecision of affinity control
Core Design Contradiction:
Ease of operationVSManufacturing precision

Solution Approach 1:

The patent applies parameter changes by systematically varying CDR loop sequences and antibody scaffold parameters through computational design. The method changes amino acid sequences in CDR regions to optimize both binding mode and affinity, using in silico mutagenesis and sequence space scanning to achieve precise control over binding characteristics.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs preliminary action by pre-selecting target epitopes and designing antibody scaffolds with predetermined binding geometries before experimental validation. The computational framework performs preliminary design and optimization in silico, including docking simulations and energy minimization, to establish binding mode control before wet lab verification.

Inventive Principle:
Principle #10Preliminary action

2Adaptability or versatility

If traditional immunization methods are used, then antibody diversity is improved, but control over epitope selection and binding specificity is lost

Engineering Contradiction:
Improveantibody diversityVSAvoidcontrol over epitope and binding specificity
Core Design Contradiction:
Adaptability or versatilityVSManufacturing precision

Solution Approach 1:

The patent uses computational design algorithms and energy minimization functions as intermediaries between the desired epitope target and the final antibody structure. This intermediary computational framework enables precise control over which epitopes are targeted and how binding occurs, while still generating diverse antibody sequences through in silico evolution and CDR resampling.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies universality by creating a computational framework that can design antibodies against any pre-selected epitope on any target protein. The method is universally applicable to different diseases, target proteins, and epitope types, providing both diversity in application and precise control over binding characteristics through the same design pipeline.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Manufacturing precision

If de novo computational design is implemented, then precision in targeting pre-selected epitopes is improved, but experimental validation remains challenging

Engineering Contradiction:
Improveprecision in targeting pre-selected epitopesVSAvoidexperimental validation success
Core Design Contradiction:
Manufacturing precisionVSReliability

Solution Approach 1:

The patent implements feedback by using experimental validation results to refine and improve the computational design framework. The method incorporates iterative optimization where experimental data on binding affinity and specificity feeds back into the computational models, improving the reliability of subsequent design iterations while maintaining precision in epitope targeting.

Inventive Principle:
Principle #23Feedback

Data Source

PatentEP3384415B1De novo antibody design
Publication Date: 2026.02.11 UCB BIOPHARMA SPRL
  • EP3384415B1 patent drawingFigure 1~2
  • EP3384415B1 patent drawingFigure 3~4
  • EP3384415B1 patent drawingFigure 5~7

AI summary

Computer-implemented methods of designing an antibody that will bind to a target epitope are disclosed. In one arrangement, the method comprises identifying one or more hotspot residues that will each bind to a corresponding one of one or more hotspot sites on the target epitope. Candidate antibody structures are selected from a database such that characteristic atoms within the antibody structure and hotspot characteristic atoms can be superimposed computationally with an averaged spatial deviation less than a predetermined threshold. A designed antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.